CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.
1 report, 1 independent
Updated Sep 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics and Scribe Therapeutics presented at a Morgan Stanley conference, highlighting their competition in gene-editing therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
-
Scribe Therapeutics
genetic medicine therapeutics company from Alameda, California
Nothing else this week.
Related events
- MarketBeat summarized current investment recommendations for CRISPR Therapeutics on November 3, 2026.
- CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.
- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.
- CRISPR Therapeutics presented clinical data at the American Society of Hematology meeting on November 4, 2026.